Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Apr 16, 2015
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how advanced MRI technology can improve radiation therapy for cancer patients. Specifically, researchers want to see if a special device called the MR-Linac, which combines MRI imaging with radiation treatment, can help doctors plan and assess treatment more effectively. Currently, MRI is mainly used for diagnosing tumors and checking how well treatment is working, but this study aims to explore its potential benefits during the actual radiation treatment process.
To participate in this study, you need to be at least 18 years old and able to undergo an MRI scan. However, certain individuals may not qualify, such as those with pacemakers or other medical devices that could be affected by strong magnets, pregnant or nursing women, and anyone who has severe anxiety about being in small spaces (claustrophobia). If you choose to participate, your current treatment plan will not change, and you'll be helping researchers gather valuable information that could enhance patient care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women age 18 or older
- Exclusion Criteria:
- • Anyone who would be normally excluded from undergoing an MRI examination as per Memorial Hospital for Cancer and Allied Diseases Screening Questionnaire
- • Participants/volunteers with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field
- • Female participants/volunteers who are pregnant or nursing
- • Participants/Volunteers who are unable to comply or complete the MRI exam due to claustrophobia or high levels of anxiety
- • Participants/Volunteers from the vulnerable population, as defined by 45 CFR 46.
- • Participants at higher risk due to age, frailty, or the emergent nature of their condition.
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Middletown, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Harrison, New York, United States
Basking Ridge, New Jersey, United States
Middletown, New Jersey, United States
Commack, New York, United States
Basking Ridge, New Jersey, United States
Montvale, New Jersey, United States
Patients applied
Trial Officials
Nancy Lee, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials